Mucoepidermoid carcinoma of the lung, response to EGFR inhibitors, EGFR and K-RAS mutations, and differential diagnosis

Lung Cancer. 2009 Jan;63(1):159-60. doi: 10.1016/j.lungcan.2008.09.007. Epub 2008 Nov 6.

Abstract

Mucoepidermoid carcinoma (MEC) of the lung needs to be carefully distinguished from other lung tumors with similar features, particularly from adenosquamous carcinoma, this latter tumor frequently showing EGFR mutations. In contrast with the data reported by Han et al in the last July issue of Lung Cancer, neither EGFR nor K-RAS mutations were observed in MEC from caucasian patients.

Publication types

  • Case Reports
  • Letter
  • Comment

MeSH terms

  • Aged
  • Carcinoma, Mucoepidermoid / diagnosis
  • Carcinoma, Mucoepidermoid / drug therapy*
  • Carcinoma, Mucoepidermoid / genetics*
  • Diagnosis, Differential
  • Epithelium / metabolism
  • ErbB Receptors / antagonists & inhibitors*
  • ErbB Receptors / genetics*
  • Female
  • Genes, ras*
  • Humans
  • Keratins / metabolism
  • Lung Neoplasms / diagnosis
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / genetics*
  • Mucin 5AC / metabolism
  • Mucins / metabolism
  • Mutation

Substances

  • MUC5AC protein, human
  • Mucin 5AC
  • Mucins
  • Keratins
  • ErbB Receptors